| Yuvezzi (U.S.N.L.M.) | |||||
|---|---|---|---|---|---|
| Dosing (presbyopia) | 1 drop in each eye once daily from the same single-dose vial | ||||
| Chem Specs | carbachol 2.75% and brimonidine tartrate 0.1% as a greenish-yellow solution | ||||
| Quantities | Carton of 30 single-dose vials (6 pouches each containing 5 vials), 0.16ml/vial. | ||||
| Cost | |||||
| Class | Carbachol, a cholinergic agonist, and brimonidine, an alpha-adrenergic receptor agonist. | ||||
| Action | Carbachol produces constriction of the iris sphincter and ciliary body. Brimonidine tartrate blocks contraction of the iris dilator and relaxes tonic contraction of the ciliary muscle, enhancing selectivity for the pupil and increasing bioavailability of carbachol in the aqueous humor. |
||||
| Usage | Indicated for the treatment of presbyopia in adults. Initial miosis typically occurs within 30 minutes, lasting between up to 10 hrs. |
||||
| Warnings | Warn patients about hazard of reduced vision with night driving or other situations involving reduced illumination. Retinal detachment is a risk with miotics. Iris - Lens synechiae may be exacerbated by miotics in patients with a history of iritis. YUVEZZI may potentiate syndromes of vascular insufficiency so use with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans. |
||||
| Contraindications | Hypersensitivity to any ingredient or excipients. | ||||
| Pediatric use | n/a | ||||
| Pregnancy | There are no adequate and well controlled studies of yuvezzi administration in pregnant women.
|
| Unpreserved. |
| ||